APR 21, 2017 01:16 PM PDT

Malaria Parasite Inspires New Bladder Cancer Drug

WRITTEN BY: Xuan Pham

The malaria parasite was the inspiration behind the newest drug for the treatment of bladder cancer. In particular, the drug derived from the malaria protein may be potent against some intractable forms of the disease.

Image credit: Pixabay.com

Bladder cancer doesn’t get as much attention as other cancers, like breast, kidney, or prostate cancer. However, bladder cancer accounts for about 5% of all new cancer cases in the U.S., and it is the fourth most prevalent cancer in men. In 2016, the American Cancer Society estimates nearly 77,000 new bladder cancer cases, which may claim more than 16,000 lives.

Though some types of bladder cancer have good prognoses, some types are resistant to standard chemotherapy treatments, such as cisplatin. This increases the risks for metastasis, which severely diminishes the survival outcomes.

To find new drug targets for bladder cancer, the research team, led by Mads Daugaard of the University of British Columbia, turned to the malaria parasite. They found that a protein derived from the parasite, called VAR2CSA, can deliver chemotherapy agents directly to the tumors. This protein targets the drug to based a sugar molecule that’s only present in cancer cells and the placenta.

"This is the first study where we put the concept of using malaria proteins for cancer therapy into a direct clinical context," said Daugaard, the study’s senior investigator. "There is a massive clinical need to find new treatments for bladder cancer and we saw an opportunity to target this disease with our new malaria drug."

In a mouse model of drug-resistant bladder cancer, the team found that the malaria protein correctly targeted the cancer drugs to the tumors. In addition, the tumors shrank in response to the the malaria drug combo. Animals treated with the malaria protein were alive for longer than the untreated control animals.

"No second line treatment option is available," said Daugaard. "We're very excited by these results because it shows that we are on our way to developing a completely new treatment option for lethal bladder cancer. It has the potential to have a tremendous impact on patient care."

The team’s next plan is scaling up the production of the VAR2CSA drug combo for clinical trials.

Additional source: University of British Columbia via EurekAlert!

 

About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
OCT 21, 2019
Cancer
OCT 21, 2019
New hope for ovarian cancer
Ovarian cancer affects roughly 1 in 78 women and although survival rates are high (over 90%) with early diagnosis, we currently do not have a way to test f...
OCT 21, 2019
Clinical & Molecular DX
OCT 21, 2019
New Device Improves Accuracy In Lung Cancer Diagnosis
Acute respiratory distress syndrome ARDS occurs when fluid builds up in the alveoli. These tiny elastics sacs, which are responsible for gaseous exchange i...
OCT 21, 2019
Cancer
OCT 21, 2019
Treating glioblastomas through the bloodstream
New research published in Nature Communications details a novel immunotherapy that is capable of treating brain cancer via the bloodstream. Although only p...
OCT 21, 2019
Cancer
OCT 21, 2019
Cancer drugs don't work the way we thought
New research recently published in the journal Science Translational Medicine surprises the oncological community with findings that a protein previously t...
OCT 21, 2019
Cancer
OCT 21, 2019
Blood test to predict prostate cancer
A study published recently in the Journal of Urology details the results from a new type of blood test that is capable of diagnosing prostate cancer. The i...
OCT 21, 2019
Cancer
OCT 21, 2019
Looking to the depths of the human genome to understand cancer
Have you ever heard of dark matter? No, I’m not talking about the dark matter of the universe – I mean the dark matter that lives within your g...
Loading Comments...